What Are PDUFA Dates and Why Do They Matter?

PDUFA stands for Prescription Drug User Fee Act. When a pharmaceutical company submits a drug application (BLA for biologics, NDA for small molecules), the FDA commits to making a decision by a specific deadline—the PDUFA date. This date is not a guarantee of approval or rejection; it's simply the deadline by which the FDA must render a decision.

PDUFA dates are critical catalysts for biotech investors because they represent binary events with enormous financial consequences. A company may spend 5-10 years and $500M+ developing a drug, only to have its fate determined by FDA approval or rejection. When the PDUFA date arrives, stock prices often move 20-50%+ in a single trading day, depending on the outcome and market expectations.

By tracking PDUFA dates and analyzing the underlying regulatory signals that predict approval probability, investors can position ahead of these catalysts and reduce binary risk. ODIN scores each PDUFA event to quantify approval odds, giving you an edge in biotech trading and investing.

Q1 2026 PDUFA Dates (January – March)

Q1 2026 features several major PDUFA catalysts, including the first validated ODIN win and multiple high-impact drug approvals expected in psychiatry, gastroenterology, oncology, and rare disease:

Table Notes: ODIN scores represent approval probability at the time of publication. Actual outcomes depend on FDA review findings, sponsor responses to information requests, and late-breaking clinical/safety data. Stock reactions vary by pre-event implied probability and gamma/vega dynamics. Dates subject to extension or update per FDA policy.

Q2–Q4 2026 PDUFA Dates

Additional PDUFA dates for Q2, Q3, and Q4 2026 are being confirmed and will be added to this calendar as companies submit applications and the FDA publishes action letters. Major therapeutic areas expected to have PDUFA activity in 2026 include:

• Oncology: Multiple novel checkpoint inhibitors, kinase inhibitors, and antibody combinations
• Neurology: Alzheimer's disease, Parkinson's, and amyotrophic lateral sclerosis (ALS) treatments
• Immunology: JAK inhibitors, biologics for autoimmune and inflammatory diseases
• Rare Disease: Gene therapies, enzyme replacement therapies (ERTs), and orphan indications
• Infectious Disease: Novel antibiotics, antivirals, and vaccines for emerging pathogens

Subscribe to PDUFA.bio's calendar alerts to receive updates as new PDUFA dates are confirmed and ODIN scores are published for each event.

How ODIN Scores Every PDUFA Date

ODIN v2.1 is PDUFA.bio's proprietary AI system that predicts FDA approval probability by analyzing 54+ weighted regulatory signals. These signals fall into six major categories:

• Mechanism & Drug Design: First-in-class status, novelty, mechanism of action, and scientific rationale. First-in-class drugs receive substantial FDA flexibility.
• Clinical Evidence: Phase 3 efficacy data, superiority vs. placebo or comparators, effect size, statistical significance, and consistency across patient populations.
• Safety & Tolerability: Adverse event profiles, serious adverse events (SAEs), discontinuation rates, and safety advantages vs. existing treatments.
• Regulatory Status: Priority Review designation, Breakthrough Therapy status, Accelerated Approval pathway, and prior FDA interactions (meetings, feedback).
• Sponsor Track Record: Company's historical success rate with FDA submissions, regulatory expertise, manufacturing quality, and prior approval outcomes.
• Precedent & Market Context: Historical FDA approval rates in the therapeutic area, competitive landscape, unmet medical need, and comparable approved drugs.

ODIN aggregates these signals using a proprietary machine learning model trained on 20+ years of FDA approval data. The output is a probability score (0-100%) and a confidence tier (TIER_1, TIER_2, or TIER_3):

• TIER_1: > 85% approval probability. High-conviction predictions with strong supporting signals.
• TIER_2: 60–85% approval probability. Moderate confidence; outcome depends on FDA review findings.
• TIER_3: < 60% approval probability. Low confidence; significant regulatory or clinical risk.

Each PDUFA date published on PDUFA.bio includes an ODIN score and tier breakdown, allowing you to quickly assess regulatory risk and position your portfolio accordingly.

How to Use This Calendar

Follow these three steps to leverage PDUFA dates for biotech investing and trading:

Step 1: Identify Upcoming Catalysts

Review this calendar to find PDUFA dates that align with your investment thesis. Are you bullish on a particular company or therapeutic area? Look for PDUFA dates that represent key value inflection points. For example, VNDA Bysanti (approved Feb 20) was a major milestone for Vanda's psychiatric franchise and de-risked the company's pipeline.

Step 2: Check ODIN Scores & Regulatory Analysis

Click on any PDUFA catalyst in this calendar to access the full ODIN score breakdown, regulatory analysis, clinical trial summaries, and historical precedent. Understand why ODIN predicted a particular approval probability. This analysis informs your position sizing and stop-loss placement.

Step 3: Monitor Risk & Set Alerts

PDUFA dates are binary events. Use PDUFA.bio's alert system to get notified 7 days before, 1 day before, and on the day of the PDUFA decision. Consider setting price alerts on the underlying stock to capture post-approval rallies or post-rejection capitulation. Many traders size positions based on ODIN's TIER classification—larger positions for TIER_1 events, smaller for TIER_3.

Featured PDUFA Catalysts & Deep Dives

Explore detailed regulatory analyses for major 2026 PDUFA dates:

Understanding Your ODIN Score

When you see an ODIN score on PDUFA.bio, here's how to interpret it:

• 89.7% TIER_1: Very high approval probability. You should seriously consider long exposure if you believe the stock underprices the approval odds. The Bysanti example showed this prediction came true.
• 74.2% TIER_1: Still strong approval probability, but with more caution. FDA could request additional data or clarification. Suitable for core positions, not all-in bets.
• 52% TIER_2: Moderate confidence. Outcome is genuinely uncertain. Consider smaller position sizes or hedging strategies like protective puts or call spreads.
• 35% TIER_3: Low approval odds. FDA likely has major concerns or the drug does not meet its efficacy endpoints. Short or avoid exposure unless stock already prices in failure.

ODIN's Validated Track Record

As of February 2026, ODIN has published predictions on 48+ PDUFA catalysts with a cumulative accuracy of 93%+ at the TIER level. This means that when ODIN predicts TIER_1 (high confidence), the drug is approved approximately 90%+ of the time. When ODIN predicts TIER_3 (low confidence), the drug is rejected or delayed approximately 65%+ of the time.

The Bysanti approval is a recent validation. ODIN's 89.7% TIER_1 score proved accurate when the FDA approved the drug one day ahead of the PDUFA deadline. This success builds on ODIN's longer track record of correctly identifying approvable molecules before market consensus solidifies.

View ODIN's complete track record to see all 48+ verified predictions and their outcomes.

Key Insights for 2026 PDUFA Investors

• 2026 is a Strong Approval Year: Q1 alone has 8 major PDUFA events across psychiatry, oncology, rare disease, and endocrinology. The FDA has historically approved > 90% of drugs that reach TIER_1 status.
• Early Approvals Signal Confidence: VNDA Bysanti's one-day-early approval suggests FDA confidence and minimal last-minute negotiation. This is distinct from extensions or day-of-deadline approvals.
• Novel Mechanisms Get Priority: First-in-class drugs (Bysanti, Kresladi gene therapy) consistently score higher ODIN approval probability than "me-too" drugs. Invest in innovation.
• Safety Differentiation Matters: In crowded therapeutic areas, demonstrated safety or tolerability advantages (metabolic, cardiac, GI) substantially boost FDA approval odds.
• Binary Events Create Trading Opportunities: PDUFA dates are often volatile catalyst events. Size positions based on ODIN TIER and implied probability to maximize risk-adjusted returns.

Hub: All PDUFA.bio Resources

Explore PDUFA.bio's complete toolkit for biotech investing:

Start Your PDUFA Trading Journey

PDUFA dates represent the most predictable binary catalysts in biotech. Unlike earnings surprises or macroeconomic shocks, PDUFA outcomes can be modeled with surprising accuracy using ODIN's framework.

The 2026 calendar is packed with high-probability approval events. Whether you're a day trader hunting PDUFA volatility or a long-term investor de-risking binary events, PDUFA.bio's ODIN scores and regulatory analysis give you the edge.

Start by:

• Bookmarking this 2026 PDUFA calendar for easy reference
• Subscribing to PDUFA.bio alerts for upcoming catalyst notifications
• Exploring deep-dive analyses for your top biotech holdings
• Using ODIN scores to size positions aligned with approval probability

Good luck with your 2026 biotech investing. May your PDUFA predictions be prescient and your stock moves be profitable.